CTOs on the Move

Taro Pharmaceutical Industries

www.taropharma.com

 
Taro Pharmaceutical Industries is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Headstrong Project

Headstrong provides cost-free, barrier-free, stigma-free mental health treatment for veterans and their families.

Ascend SpecialtyRx

Ascend SpecialtyRx is a Port Washington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tricida

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.

ITM Isotope Technologies Munich SE

ITM Isotopen Technologien München AG and its subsidiaries develop, produce and supply innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals.

SubjectWell

SubjectWell provides risk-free patient recruitment for clinical trials. We engage the 96% of Americans who have never participated in clinical trials and we only charge for those who randomize.